Rigel Pharmaceuticals, Inc.
395 articles with Rigel Pharmaceuticals, Inc.
-
Rigel to Participate in Three Upcoming Investor Conferences in September 2021
9/2/2021
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in September.
-
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
9/1/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19
-
New data is coming out every day about COVID-19 and the body’s response to vaccines. Here’s a look at some of the top stories.
-
As the COVID-19 pandemic continues with surges in the U.S. in unvaccinated people, biopharma companies are still working on new vaccines and therapies against the disease.
-
Rigel Pharmaceuticals Provides Update on COVID-19 Program
8/13/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time.
-
Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update
8/3/2021
Rigel Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2021, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
-
Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update
7/27/2021
Rigel Pharmaceuticals, Inc. announced that it will report its second quarter 2021 financial results after market close on Tuesday, August 3, 2021.
-
New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
7/14/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place online from July 17 – 21, 2021.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look. -
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
6/29/2021
Rigel Pharmaceuticals, Inc. today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health ACTIV-4 trial.
-
Here’s a look at some of the top COVID-19-related stories for today.
-
Rigel to Present at the Jefferies Virtual Healthcare Conference
5/26/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m. Eastern Time .
-
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
5/14/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L. Hannah, M.D. to its Board of Directors.
-
Rigel Reports First Quarter 2021 Financial Results and Provides Business Update
5/5/2021
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2021, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update
4/28/2021
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on Wednesday, May 5 , 2021. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time )
-
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
4/13/2021
Broad and consistent improvement in clinical outcomes including serious adverse events, mortality, ordinal scale assessment and number of days in the ICU Rigel plans to share these results with health authorities, including the US FDA Conference call and webcast today at 8:00 am ET/5:00 am PT
-
Rigel Announces Closing of Strategic Collaboration with Lilly
4/7/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
3/11/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor,